Title |
Intravenous Mesenchymal Stem Cells Improve Survival and Motor Function in Experimental Amyotrophic Lateral Sclerosis
|
---|---|
Published in |
Molecular Medicine, April 2012
|
DOI | 10.2119/molmed.2011.00498 |
Pubmed ID | |
Authors |
Antonio Uccelli, Marco Milanese, Maria Cristina Principato, Sara Morando, Tiziana Bonifacino, Laura Vergani, Debora Giunti, Adriana Voci, Enrico Carminati, Francesco Giribaldi, Claudia Caponnetto, Giambattista Bonanno |
Abstract |
Despite some advances in the understanding of amyotrophic lateral sclerosis (ALS) pathogenesis, significant achievements in treating this disease are still lacking. Mesenchymal stromal (stem) cells (MSCs) have been shown to be effective in several models of neurological disease. To determine the effects of the intravenous injection of MSCs in an ALS mouse model during the symptomatic stage of disease, MSCs (1 × 10⁶) were intravenously injected in mice expressing human superoxide dismutase 1 (SOD1) carrying the G93A mutation (SOD1/G93A) presenting with experimental ALS. Survival, motor abilities, histology, oxidative stress markers and [³H]D-aspartate release in the spinal cord were investigated. MSC injection in SOD1/G93A mice improved survival and motor functions compared with saline-injected controls. Injected MSCs scantly home to the central nervous system and poorly engraft. We observed a reduced accumulation of ubiquitin agglomerates and of activated astrocytes and microglia in the spinal cord of MSC-treated SOD1/G93A mice, with no changes in the number of choline acetyltransferase- and glutamate transporter type 1-positive cells. MSC administration turned around the upregulation of metallothionein mRNA expression and of the activity of the antioxidant enzyme glutathione S-transferase, both associated with disease progression. Last, we observed that MSCs reverted both spontaneous and stimulus-evoked neuronal release of [³H]D-aspartate, a marker of endogenous glutamate, which is upregulated in SOD1/G93A mice. These findings suggest that intravenous administration of MSCs significantly improves the clinical outcome and pathological scores of mutant SOD1/G93A mice, thus providing the rationale for their exploitation for the treatment of ALS. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Korea, Republic of | 2 | 2% |
United States | 2 | 2% |
Spain | 1 | <1% |
Japan | 1 | <1% |
Unknown | 103 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 22 | 20% |
Student > Master | 18 | 17% |
Student > Ph. D. Student | 15 | 14% |
Student > Bachelor | 13 | 12% |
Student > Doctoral Student | 4 | 4% |
Other | 13 | 12% |
Unknown | 24 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 21 | 19% |
Medicine and Dentistry | 20 | 18% |
Biochemistry, Genetics and Molecular Biology | 10 | 9% |
Neuroscience | 9 | 8% |
Nursing and Health Professions | 4 | 4% |
Other | 16 | 15% |
Unknown | 29 | 27% |